Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-05-23Clinical Trial Update: Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia [Phase 3]
Phase 3 trial evaluating rituximab, fludarabine, and cyclophosphamide versus observation in early-stage chronic lymphocytic leukemia complet…
-
CLINICAL_TRIALS trial_result · 2019-05-23Clinical Trial Update: Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial assessing bendamustine combined with rituximab in patients with previously untreated or relapsed chronic lymphocytic leukemia …
-
CLINICAL_TRIALS trial_result · 2019-05-23Clinical Trial Update: Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia [Phase 3]
Phase 3 trial evaluating fludarabine with or without cyclophosphamide in advanced chronic lymphocytic leukemia has been completed.
-
CLINICAL_TRIALS trial_result · 2019-05-21Clinical Trial Update: PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia [Phase 2]
Phase 2 results for Ibrutinib (PCI-32765) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and B-cell pro…
-
EMA withdrawal · 2019-05-10EMA Withdrawn: Arzerra (ofatumumab) — Novartis Europharm Ltd
EMA has withdrawn Arzerra (ofatumumab) from the market in Europe.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-05-08Clinical Trial Update: Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients [Phase 2]
Phase 2 clinical trial evaluating a sequential regimen of bendamustine followed by GA101 and ibrutinib in patients with chronic lymphocytic …
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial evaluating lenalidomide plus ofatumumab in previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma; comp…
-
FDA approval · 2019-04-23FDA Approved: CAMPATH — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for CAMPATH (alemtuzumab) submitted by Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating tandem CAR T cells targeting CD19 and CD22 for relapsed or chemotherapy-refractory B-cell malignancies.
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [Phase 3]
Phase 3 trial comparing ibrutinib+obinutuzumab vs chlorambucil+obinutuzumab in treatment-naïve CLL/SLL; study completed with results posted …
-
CLINICAL_TRIALS trial_result · 2019-03-14Clinical Trial Update: A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status [Phase 4]
Phase 4 trial comparing Mabthera (rituximab) with FCR versus Mabthera with chlorambil in chronic lymphocytic leukemia with unfavorable somat…
-
CLINICAL_TRIALS trial_result · 2019-02-27Clinical Trial Update: Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL [Phase 2]
Phase 2 trial of pentostatin, cyclophosphamide, and rituximab followed by Campath-1H in relapsed/refractory B-cell chronic lymphocytic leuke…
-
CLINICAL_TRIALS trial_result · 2019-02-26Clinical Trial Update: Dose Optimization Trial of CD19 Redirected Autologous T Cells [Phase 2]
Phase 2 dose optimization trial of CD19 redirected autologous T cells in adults with relapsed/refractory CLL or SLL has completed with poste…
-
CLINICAL_TRIALS trial_result · 2019-02-22Clinical Trial Update: Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL [Phase 1]
A Phase 1 trial evaluating adding SNX-5422 to an established dose of ibrutinib in chronic lymphocytic leukemia was terminated; the update co…
-
CLINICAL_TRIALS research · 2019-02-01Clinical Trial Update: Observational Study in CLL Patients Receiving BR
This entry notes the completion of an observational study in chronic lymphocytic leukemia patients treated with the BR regimen (bendamustine…
-
CLINICAL_TRIALS research · 2019-02-01Clinical Trial Update: A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL [Phase 1]
Phase I trial evaluating AC0010 in patients with CLL/SLL, mantle cell lymphoma, diffuse large B-cell lymphoma, and other non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: GIMEMA CLL0809 Study (BendOfa) [Phase 2]
Phase 2 GIMEMA CLL0809 trial (BendOfa) in chronic lymphocytic leukemia; the study in relapsed or refractory CLL after up to two prior lines …
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: CLL Empirical Antibiotic Regimen [Phase 2]
This document provides an update on a Phase 2 clinical trial evaluating an empirical antibiotic regimen for chronic lymphocytic leukemia (CL…
-
CLINICAL_TRIALS withdrawal · 2019-01-25Clinical Trial Update: Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. [Phase 1]
A Phase 1 trial evaluating obinutuzumab in combination with high-dose ibrutinib for chronic lymphocytic leukemia patients with progression o…
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) [Phase 2]
Phase 2 study evaluating novel approaches to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation, with res…
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]
A phase 1/2 trial evaluating chlorambucil with lenalidomide and lenalidomide maintenance in untreated elderly patients with chronic lymphocy…
-
CLINICAL_TRIALS trial_result · 2019-01-22Clinical Trial Update: Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy [Phase 1, Phase 2]
Phase 1/2 clinical trial of lenalidomide in combination with fludarabine and cyclophosphamide for advanced chronic lymphocytic leukemia not …
-
CLINICAL_TRIALS trial_result · 2019-01-18Clinical Trial Update: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation [Phase 1]
Phase 1 trial evaluating inducible regulatory T cells (iTregs) in non-myeloablative sibling donor peripheral blood stem cell transplantation…
-
FDA approval · 2019-01-18FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s original application for a generic cyclophosphamide product. This marks approval of a generic formulation …
-
FDA approval · 2019-01-16FDA Approved: CAMPATH — Supplemental Application (Genzyme Corporation)
FDA overview of a supplemental application for CAMPATH (alemtuzumab) submitted by Genzyme Corporation.